Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$42.21 USD

42.21
433,723

-0.56 (-1.31%)

Updated May 8, 2024 04:00 PM ET

After-Market: $43.50 +1.29 (3.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Amphastar (AMPH) Could Beat Earnings Estimates Again

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

New Strong Sell Stocks for April 26th

AMPH, BCML and DHC have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2024.

Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $41.52, representing a -1% change from its previous close.

Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $44.03, signifying a -1.21% move from its prior day's close.

New Strong Sell Stocks for March 18th

ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.

Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.

Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?

Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.

Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know

Amphastar Pharmaceuticals (AMPH) reachead $55.51 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

Smart Beta ETF report for JSML

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $55.61, denoting a +1.85% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Market: What You Should Know

In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $52.35, marking a -0.85% move from the previous day.

Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know

In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree

Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree are part of the Zacks top Analyst Blog.

Tirthankar Chakraborty headshot

5 Top Growth Stocks to Buy as Recession Fears Subside

Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.

Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's

Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.